55 - DISCREPANCY OF GLYCAEMIC RANGES IN REGARD TO CGM METRICS FOR CLINICAL CARE VERSUS GUIDANCE FOR GLYCAEMIC TARGETS WITHIN THE RECENT CONSENSUS ON TIR
Abstract
Background and Aims
The international consensus regarding clinical targets for continuous glucose monitoring defined percentages of total time people with type 1 diabetes (PWT1D) should spend in specified glycaemic ranges. According to the statement TBR-level 1 is defined as glucose concentrations 54-69mg/dL and TAR-level 1 181-250mg/dL, which is contrary to their recommendations regarding the guidance for the assessment of glycaemic control (TBR-level 1 <70mg/dL, TAR-level 2 >180mg/dL). The aim of this retrospective observational study was to assess if this discrepancy leads to different results for time spent in glycaemic ranges.
Methods
PWT1D (n=100, 49 female vs. 51 male, HbA1c 7.4±0.8%; age 42±14 years, 19 CSII, 81 MDI) used a flash glucose monitoring (FlashGM) system for 3 months from which >80% of the sensor data were available. FlashGM data were compared depending on the aforementioned recommendations via paired t-tests (p≤0.05) (Table 1).
Results
Table 1
| Standardized CGM metrics for clinical care | Guidance for glycaemic targets | p-value | ||
| TBR-level 2 <54 mg/dL | 2.0±2.2% | TBR-level 2 <54 mg/dL | 2.0±2.2% | n/a |
| TBR-level 1 54-69 mg/dL | 3.6±2.3% | TBR-level 1 <70 mg/dL | 5.6±4.3% | p<0.0001 |
| TIR 70-180 mg/dL | 55.1±15.8% | TIR 70-180 mg/dL | 55.1±15.8% | n/a |
| TAR-level 1 181-250 mg/dL | 24.0±7.5% | TAR-level 1 >180 mg/dL | 39.3±17.1% | p<0.0001 |
| TAR-level 2 >250 mg/dL | 15.3±11.3% | TAR-level 2 >250 mg/dL | 15.3±11.3% | n/a |
| 100±0% | 117.3±11.1% | p<0.0001 | ||
Conclusions
Our results showed a difference between the standardized CGM metrics for clinical care versus guidance for glycaemic targets hence leading to different percentages in pre-specified glycaemic ranges.
